Home›Companies›Exin Therapeutics
Exin Therapeutics

Agentic platform for predictive neuro drug discovery + data foundry.

We are developing therapies for disorders driven by dysfunctional neural circuits. To develop these therapies, we are building an agentic discovery platform that learns from experiments in our own in vivo lab. Our agents use CircuitATLAS to connect disease phenotypes with the neural circuits, cell types and molecular mechanisms, identify therapeutic targets and design experiments to test them. Our cross-species models learn from large-scale neural activity data to identify conserved circuit states and help predict how an intervention’s effects may translate from preclinical models to humans. At our Data Foundry in Manila, our team of RAs test these hypotheses in vitro and in vivo. The results refine our models and guide the next set of experiments. This lab-in-the-loop approach allows our agents to develop and test ideas against experimental evidence throughout discovery. We are starting with epilepsy, with the goal of developing first-in-class therapies across a full spectrum of disorders driven by dysfunctional brain activity. Publications: - CircuitATLAS (https://arxiv.org/abs/2610.09643). Target discovery platform which combines mechanistic reasoning with an in vivo lab-in-the-loop. AI agents identify therapeutic targets and design experiments that our research teams execute in the lab. The resulting biological data feeds back into the discovery process to iteratively refine hypotheses and validate new interventions. - Cross species representation learning (https://arxiv.org/abs/2610.11222). Aligning mouse and human neural activity to predict clinical drug efficacy from preclinical data.
Active Founders
Neuroscientist with a background in biochemistry and research on gene therapy, pancreatic cancer, and muscle physiology at institutions in Boston, Vienna, and Stockholm. Earned MSc in Neuroscience and PhD in Pharmacology at Oxford Uni, focusing on neurodevelopment and the effects of SSRI anti-depressants on early patterns of neural activity. Used neuroAI models at the Gatsby Unit (UCL) to study serotonin’s role in cognition. Currently developing gene therapies for neurological conditions.
Marko Tvrdic
Marko Tvrdic
Founder/COO
Co-founder at Exin Therapeutics.
Company Launches
Exin Therapeutics: An AI discovery platform for neurotherapeutics
See original launch post

Exin Therapeutics uses AI and high-throughput mouse studies to develop therapies for people suffering from neurological and neuropsychiatric disorders. We are tackling conditions like epilepsy, debilitating symptoms of autism spectrum disorder (ASD), and Parkinson’s disease by focusing on the neural circuitry of the brain.

Why is this important?

Millions of people around the world suffer from neurological disorders. These disorders arise from imbalances in brain activity. Think of it like an orchestra where some instruments are playing too loud while others are too quiet. This “bad music” / neural imbalance—what we call excitatory/inhibitory (E/I) imbalance—is the root cause of many symptoms in these disorders. For example, in epilepsy, overactive circuits lead to seizures, while in ASD, it can cause sensory hypersensitivities - where individuals feel overwhelmed by normal sounds, lights, or touch that most people wouldn't even notice. These dysregulations in neural circuits impact how the brain processes information and responds to the world, leading to the debilitating symptoms we see in these disorders.

Our solution

We’re taking a circuit-level approach to treating brain disorders. Instead of trying to restore missing genes, we’re supplementing already existing genes that we know will be directly changing the neural activity in the brain - in the direction that we want and independently of the genetic background.

uploaded image

We are also working on a multimodal AI model to streamline our preclinical R&D. Why? Well, because developing drugs for the brain is really tough. Every candidate needs to be tested for its ability to modulate circuits, and doing that through a traditional drug development preclinical pathway is a slow process.

Because of that, we use ML to analyze high-density multimodal data sets and prioritize which drugs are worth testing further. We use neural activity, behavior, and transcriptomics to train multimodal AI models that identify the drivers of the disease not observable by conventional analytical methods.

uploaded image

Then, we use these models to (1) predict the potential of our therapies to treat particular indications and (2) provide an efficacy readout during our internal experimental testing. This way, we spend our time (and funding) testing the most promising candidates.

Our ask

  1. Intros: If you have contacts in pharma, working on complementary tech, or have ideas for partnerships, we’d love to connect.
  2. We'd love to hear from people who have worked in therapeutics and people with IND-enabling programs or clinical trial design experience.

Team

We are a team of 3 Oxford-educated neuroscientists. Gabriel is a biochemist with a wealth of research experience in neural development, gene therapy, and NeuroAI. He holds a PhD in Pharmacology from Oxford. Ivan is a physicist by training and has worked in molecular biology, circuit, and systems neuroscience. Ivan’s brother suffers from ASD and Ivan is on a mission to improve the quality of life for patients suffering from debilitating neurological conditions. He holds a PhD in neuroscience from Oxford. Marko has experience with iPSC models, retinal disorders, and circadian and developmental neuroscience. During his PhD, he worked in systems and behavioral neuroscience and holds an MSc from Oxford.

uploaded image

We are supported by a team of advisors from top industry and academic institutions - including Harvard & UCL.

YC Photos
Exin Therapeutics
Founded:2024
Batch:Winter 2025
Team Size:9
Status:
Active
Location:San Francisco
Primary Partner:Jared Friedman